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Abstract 53 
Rationale: There are several methods to measure cardiomyocyte (CM) and muscle contraction but 54 
these require customized hardware, expensive apparatus and advanced informatics or can only be 55 
used in single experimental models. Consequently, data and techniques have been difficult to 56 
reproduce across models and laboratories, analysis is time consuming and only specialist researchers 57 
can quantify data.  58 
Objective: Here we describe and validate an automated, open source software tool 59 
(MUSCLEMOTION) adaptable for use with standard laboratory- and clinical imaging equipment that 60 
enables quantitative analysis of normal cardiac contraction, disease phenotypes and pharmacological 61 
responses. 62 
Methods and Results: MUSCLEMOTION allowed rapid and easy measurement of contractility from 63 
high-speed movies in: (i) 1-dimensional in vitro models such as isolated adult and human pluripotent 64 
stem cell-derived CMs (hPSC-CMs); (ii) 2-dimensional in vitro models, such as beating CM 65 
monolayers or small clusters of hPSC-CMs; (iii) 3-dimensional multicellular in vitro or in vivo 66 
contractile tissues such as cardiac "organoids", engineered heart tissues (EHT), zebrafish- and human 67 
hearts. MUSCLEMOTION was effective under different recording conditions (bright field 68 
microscopy with simultaneous patch clamp recording, phase contrast microscopy and traction force 69 
microscopy). Outcomes were virtually identical to the current gold standards for contraction 70 
measurement such as optical flow, pole deflection, edge-detection systems or manual analyses. 71 
Finally, we used the algorithm to quantify contraction in in vitro and in vivo arrhythmia models and to 72 
measure pharmacological responses. 73 
Conclusions: Using a single open source method for processing video recordings, we obtained 74 
reliable pharmacological data and measures of cardiac disease phenotype in experimental cell-, 75 
animal- and human models. 76 
 77 
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Non-standard Abbreviations and Acronyms 79 
AP action potential 80 
CM cardiomyocyte 81 
EHT Engineered Heart Tissue 82 
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HCM hypertrophic cardiomyopathy  84 
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ISO isoprenaline 86 
LQT1 Long QT Syndrom Type 1 87 
MEA multi electrode array 88 
NIFE nifedipine 89 
PDMS polydimethylsiloxane 90 
SNR signal-to-noise ratio 91 
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 94 
Introduction 95 
The salient feature of cardiomyocytes (CMs) is their ability to undergo cyclic contraction and 96 
relaxation, a feature critical for cardiac function. In many research laboratories and clinical settings it 97 
is therefore essential that cardiac contraction can be quantified at multiple levels, from single cells to 98 
multicellular or intact cardiac tissues. Measurement of contractility is relevant for analysis of disease 99 
phenotypes, cardiac safety pharmacology, and longitudinal measures of cardiac function over time, 100 
both in vitro and in vivo. In addition, human genotype-phenotype correlations, investigation of cardiac 101 
disease mechanisms and the assessment of cardiotoxicity are increasingly performed on human 102 
induced pluripotent stem cells (hiPSCs) derived from patients1-3. Many of these studies are carried out 103 
in non-specialist laboratories so that it is important that analysis methods are simplified such that they 104 
can be used anywhere with access to just standard imaging equipment. Here, we describe a single 105 
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method with high versatility that can be applied to most imaging outputs of cardiac contraction likely 106 
to be encountered in the laboratory or clinic. 107 
Electrical and calcium signals are usually quantified in vitro using established technologies such as 108 
patch clamp electrophysiology, multi electrode arrays (MEAs), cation-sensitive dyes or cation-109 
sensitive genetic reporters4. Although experimental details differ among laboratories, the values for 110 
these parameters are with some approximations comparable across laboratories, cardiomyocyte source 111 
and cell culture configuration (e.g. single cells, multicellular 2-Dimensional (2D) CM monolayers, 3-112 
Dimensional (3D) cultures)5,6. However, there is no comparable method for measuring cardiac 113 
contraction across multiple platforms, despite this being a crucial functional parameter affected by 114 
many diseases or drugs7. We have developed a method to address this that is built on existing 115 
algorithms and is fully automated, but most importantly can be used on videos, image stacks or image 116 
sequences loaded in the open source image processing program ImageJ8. Moreover, it is an open 117 
source, dynamic platform that can be expanded, improved and integrated for customized applications. 118 
The method, called MUSCLEMOTION, determines dynamic changes in pixel intensity between 119 
image frames and expresses the output as a relative measure of displacement contractility during 120 
muscle contraction and relaxation. We applied the concept to a range of biomedical- and 121 
pharmacologically relevant experimental models that included single hPSC-CMs, patterned- or 2D 122 
cultures of hPSC-CMs, cardiac organoids, engineered heart tissues (EHTs) and isolated adult rabbit 123 
CMs. Results were validated by comparing outputs of the tool with those from three established 124 
methods for measuring contraction: optical flow, post deflection and fractional shortening of 125 
sarcomere length. These methods have been tailored to (or only work on) specific cell configurations. 126 
Traction force microscopy, fractional shortening of sarcomere length and microposts are 127 
predominantly suitable for single cells8,9. Cardiomyocyte edge or perimeter detection is suitable for 128 
adult CMs but challenging for immature hPSC-CMs due to poorly defined plasma membrane borders 129 
and concentric contraction10, while large post deflection is suitable for EHTs or small cardiac 130 
bundles11 but less so for single cells. Our MUSCLEMOTION software by contrast can be used for all 131 
of these applications without significant adaptions. Furthermore, it can be used for multi-parameter 132 
recording conditions and experimental settings using transmitted light microscopy, fluorescent 133 
membrane labeling, fluorescent beads embedded in soft substrates or patch clamp video recordings. 134 
Drug responses to positive and negative inotropic agents were evaluated across four different 135 
laboratories in multiple cell configurations using MUSCLEMOTION with reliable predictions of drug 136 
effects from all laboratories. Furthermore, MUSCLEMOTION was also applicable to optical 137 
recordings of zebrafish hearts in vivo, where it represented a significant time-saving in analysis, and in 138 
human echocardiograms. This versatile tool thus provides a rapid and straightforward way to detect 139 
disease phenotypes and pharmacological responses in vitro and in vivo. 140 
 141 
 142 
Methods 143 
Extended methods are in the Online Supplements. The datasets generated and/or analyzed during the 144 
current study are available from the corresponding authors on reasonable request. 145 
Code Availability 146 
MUSCLEMOTION source code has been written in the ImageJ Macro Languageis and is included in 147 
the Online Supplements and is available for use and further development.  148 
Model Cell  149 
The in silico cardiomyocyte-like model (Fig. 1d,f,g) was created using Blender v2.77.  150 
Optical Flow analysis 151 
Optical flow analysis was implemented in LabVIEW as described by Hayakawa et al.12,13. 152 
Generation of hiPSC-HCM isogenic triplet using CRISPR/Cas9 153 
Heterozygous and homozygous mutations were introduced in the ReBL-PAT hiPSC line.  154 
hPSC Culture and Differentiation 155 
hPSCs from multiple independent cell lines (Table S1) were differentiated to CMs as previously 156 
described14-17, or with the Pluricyte® Cardiomyocyte Differentiation Kit (Pluriomics b.v.) according 157 
to the manufacturer’s protocol. Experiments were performed at 18-30 days after initiation of 158 
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differentiation, depending on the cell source and configuration. Pluricytes® were kindly provided by 159 
Pluriomics b.v. 160 
Patch Clamp Recordings on hPSC-CMs 161 
Electrophysiological recordings of isolated hPSC-CMs were performed as previously described16.  162 
MEA Recordings on hPSC-CMs 163 
Field potentials from MEAs were recorded and analyzed as previously published 18. 164 
Movement of embedded beads  165 
Gelatin-patterned polyacrylamide gels containing fluorescent beads were generated and analyzed as 166 
described previously19. 167 
Monolayers of hPSC-CMs 168 
25k-40k cells were plated per Matrigel-coated glass ø10 mm coverslip.  169 
Cardiac Organoids 170 
Cardiac organoids composed of hPSC-CMs and hPSC-derived endothelial cells, were generated as 171 
previously described17.  172 
Adult cardiomyocytes 173 
CMs were isolated from New Zealand White male rabbits as previously described 20.  174 
Membrane labelling 175 
hPSC-CMs were plated on Matrigel-coated glass-bottom 24-well plates and labelled with CellMask 176 
Deep Red according to the manufacturer’s instructions. 177 
Engineered heart tissues 178 
EHTs were generated and analyzed as previously described14.  179 
Zebrafish hearts 180 
Zebrafishes hearts were recorded, treated and analysed as previously described 23. 181 
Echocardiograms 182 
Anonymized ultrasounds of 5 adult patients were selected from the echocardiography database of the 183 
Leiden University Medical Center.  184 
Statistics  185 
One-way ANOVA for paired or unpaired measurements was applied to test the differences in means 186 
on normalized drug effects. P-values obtained from two-tailed pairwise comparisons were corrected 187 
for multiple testing using Bonferroni’s method. Statistical analyses were performed with R v3.3.3. P-188 
values lower than 0.05 were considered statistically significant and indicated with an asterisk (*). N-189 
values represent biological repeats. 190 
 191 
 192 
Results 193 
Algorithm development  194 
The principle underlying the algorithm of MUSCLEMOTION is the assessment of contraction using 195 
an intuitive approach quantifying absolute changes in pixel intensity between a reference frame and 196 
the frame of interest, which can be described as  197 
 198 
|𝑖𝑚𝑔𝑖 −  𝑖𝑚𝑔𝑟𝑒𝑓| =  𝑖𝑚𝑔𝑟𝑒𝑠𝑢𝑙𝑡  199 
 200 
where 𝑖𝑚𝑔𝑖 is the frame of interest, 𝑖𝑚𝑔𝑟𝑒𝑓 is the reference frame and 𝑖𝑚𝑔𝑟𝑒𝑠𝑢𝑙𝑡 is the resulting 201 
image. For every pixel in the frame, each reference pixel is subtracted from the corresponding pixel of 202 
interest and the difference is presented in absolute numbers. Unchanged pixels result in low (black) 203 
values, while pixels that are highly changed result in high (white) values (Fig. 1a). Next, the mean 204 
pixel intensity of the resulting image is measured. This is a quantitative measure of how much the 205 
pixels have moved compared to the reference frame: more white pixels indicate more changing pixels 206 
and, thus, more displacement. When a series of images is analysed relative to the same reference 207 
image, the output describes the accumulated displacement over time (measure of displacement, Fig. 208 
1b). 209 
However, if a series of images is analysed with a reference frame that depends on the frame of interest 210 
(e.g. 𝑖𝑚𝑔𝑟𝑒𝑓 = 𝑖𝑚𝑔𝑖−1), this results in a measure of the relative displacement per interframe interval. 211 
We defined this parameter as contraction velocity (measure of velocity, Fig. 1b). 212 
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Since velocity is the first derivative of displacement in time, the first derivative of the 213 
measure of displacement should resemble the measure of velocity derived from image calculations. 214 
To test the linearity of the method, three movies of moving blocks were analysed. The block moved 215 
back and forth at two different speeds in each direction (where 𝑣2 = 2 ∙ 𝑣1): i) along the x-axis, ii) 216 
along the y-axis and iii) along both axes (Movie S1). As expected, the measure of displacement and 217 
velocity showed a linear correlation (Fig. S1). This does not hold when the position of the block in 218 
𝑖𝑚𝑔𝑖 does not overlap the position of the block in 𝑖𝑚𝑔𝑟𝑒𝑓, with a consequent saturation in the 219 
measure of displacement (i.e. max pixel white value, Fig. S2). Therefore, comparison of the 220 
differentially derived velocities should approximately overlap in the absence of pixel saturation. This 221 
was used as a qualitative parameter to determine whether the algorithm outputs were reliable.  222 
 223 
Algorithm implementation 224 
MUSCLEMOTION was then modified to handle typical experimental recordings by (i) improving the 225 
signal-to-noise ratio (SNR), (ii) automating reference frame selection and (iii) programming built-in 226 
checks to validate the generated output data (Fig. 1c). The SNR was increased by isolating the pixels 227 
of interest in a three-step process: i) maximum projection of pixel intensity in the complete 228 
displacement contraction stack, ii) creation of a binary image of this maximum projection with a 229 
threshold level equal to the mean grey value plus standard deviation and iii) multiplication of the pixel 230 
values in this image by the original contraction displacement and speed of the contraction 231 
displacement image stack (Fig. S3). This process allowed the algorithm to work on a region of 232 
interest with movement above the noise level only. 233 
Next, a method was developed to identify the correct 𝑖𝑚𝑔𝑟𝑒𝑓 from the speed of displacement 234 
contraction image stack by comparing values obtained from the frame-to-frame calculation with their 235 
direct neighbouring values, while also checking for the lowest absolute value (Fig. S4).  236 
The reliability of MUSCLEMOTION for structures with complex movements was validated using a 237 
custom-made contracting 3D “synthetic CM” model (Fig. 1d,f,g) that was adapted to produce 238 
contractions with known amplitude and duration. Linearity was preserved during the analysis of the 239 
contraction and velocity; other output parameters of the analysis matched the input parameters (Fig. 240 
1e). A second 3D model (Fig. 1g), with a repetitive pattern aimed to create out-of-bounds problems 241 
was also generated. As expected, contraction amplitude information here was not linear (Fig. 1e), 242 
although contraction velocity and temporal parameters did remain linear (Fig. 1e,g). To mitigate this 243 
problem, we implemented an option for a 10-sigma Gaussian blur filter that can be applied on demand 244 
to biological samples that presented highly repetitive patterns (e.g. sarcomeres in adult CMs).  245 
 246 
 247 
Algorithm application to multiple cell configurations and correlation with existing gold 248 
standards  249 
This set of experiments aimed to investigate the versatility of MUSCLEMOTION and examine how 250 
its performance compared with standard measures used in each system: i) optical flow for isolated 251 
hPSC-CMs, monolayers and organoids; ii) post deflection for EHT; iii) sarcomere length fractional 252 
shortening for adult CMs. Remarkably, standard methods currently used measure only contraction or 253 
contraction velocity. Linearity was preserved in all cases during the analyses, demonstrating the 254 
reliability of the results (Fig. S5).  255 
First, single hPSC-CMs (Fig. 2a, Movie S2) exhibited concentric contraction (Fig. 2a ii) and 256 
contraction velocity amplitudes correlated well with the amplitudes obtained by optical flow analysis 257 
(R2 = 0.916) (Fig. 2a v). In contrast to single cells, the area of displacement contraction for hPSC-CM 258 
monolayers was distributed heterogeneously throughout the whole field (Fig. 2b ii, Movie S3). 259 
Optical flow analysis was compared with our measure of velocity (Fig. 2b iv); this showed a good 260 
linear correlation (R2 = 0.803) (Fig. 2b v). Complex (mixed, multicellular) 3D configurations were 261 
also investigated by analyzing hPSC-derived cardiac organoids17 (Movie S4) and EHTs14 (Movie S5). 262 
Cardiac organoids showed moderate levels of displacement contraction throughout the tissue (Fig. 2c 263 
ii), while the EHTs showed high deflection throughout the bundle (Fig. 2d ii). The contraction 264 
velocity of the organoids correlated well with the output of optical flow analysis (R2 = 0.747, Fig. 2c 265 
v). Similarly, contraction amplitudes in EHTs showed high linear correlation (R2 = 0.88919) with the 266 
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absolute force values derived from measurement of pole deflection (Fig. 2d v). Finally, single adult 267 
rabbit ventricular CMs were analyzed (Fig. 2e, Movie S6). Large displacements movement were was 268 
evident around the long edges of the CM (Fig. 2e ii). These cells were analyzed with a 10-sigma 269 
Gaussian blur filter, which also minimized (unwanted) effects of transverse movements on contraction 270 
patterns. Linearity was preserved (Fig. S5) despite the repetitive pattern of the sarcomeres and this 271 
resulted in accurate measures of both contraction (Fig. 2e iii) and speed of contraction (Fig. 2e iv). 272 
The contraction amplitude of the adult CMs stimulated at 1 Hz correlated well with the output of 273 
sarcomeric shortening using fast Fourier transform analysis21 (R2 = 0.871, Fig. 2e v). Thus, the 274 
MUSCLEMOTION algorithm yielded data in these initial studies comparable with methods of 275 
analysis tailored for the individual platforms. 276 
Application of MUSCLEMOTION to multiple imaging and recording platforms 277 
To examine whether MUSCLEMOTION could potentially be used in applications that measure other 278 
aspects of CMs functionality in parallel, we first determined the electrophysiological properties of 279 
hPSC-CMs using patch clamp whilst recording their contractile properties through video imaging. 280 
This allowed simultaneous quantitative measurement of action potentials (APs) and contraction (Fig. 281 
3a), for in-depth investigation of their interdependence. We observed a typical22 profile of AP 282 
followed by its delayed contraction.  283 
To measure contractile force in combination with contractile velocity in single CMs, we integrated 284 
fluorescent beads into polyacrylamide substrates patterned with gelatin (Fig. 3b), where the 285 
displacement of the beads is a measure of CM contractile force19 (Movie S7).  286 
Field potentials and contraction profiles of hPSC-CMs were analyzed from simultaneous electrical 287 
and video recordings of monolayers plated on MEAs (Fig 3c, Movie S8). 288 
Similarly, effective quantification of contraction profiles was obtained for fluorescently labeled 289 
hPSC-CM monolayer cultures (Fig. 3dc, Movie S98), allowing MUSCLEMOTION to be integrated 290 
on high speed fluorescent microscope systems for automated data analysis. 291 
 292 
Application of MUSCLEMOTION to drug responses in different cell models in different 293 
laboratories  294 
Having shown that MUSCLEMOTION was fit-for-purpose in analyzing contraction over a variety of 295 
platforms, we next sought to demonstrate its ability to detect the effects of positive and negative 296 
inotropes. This is essential for ensuring the scalability of the tool over multiple platforms, particularly 297 
in the context of hiPSC-CMs where regulatory authorities and pharmaceutical companies are 298 
interested in using these cells as human heart models for drug discovery, target validation or safety 299 
pharmacology23. For isoprenaline (ISO) and nifedipine (NIFE) the main parameters of interest are: 300 
contraction amplitude (ISO, NIFE), relaxation time (ISO) and contraction duration (NIFE). 301 
 302 
The relaxation time of spontaneously beating isolated hPSC-CMs on gelatin patterned polyacrylamide 303 
substrates treated with ISO significantly decreased as expected at doses higher than 1 nM. Similar to 304 
what has been reported27, contraction amplitude decreased at doses higher than 1 nM. NIFE treatment 305 
decreased both contraction amplitude and duration starting from 3 nM, respectively (Fig. 4a). In 306 
paced (1.5 Hz) hPSC-CMs monolayers, no significant effects were measured after addition of ISO on 307 
either relaxation time or contraction amplitude. NIFE caused a progressive decrease in contraction 308 
duration and amplitude in a concentration-dependent manner starting at 100 nM (Fig. 4b). Similarly, 309 
cardiac organoids paced at 1.5 Hz showed no significant effects on both relaxation time and 310 
contraction amplitude with ISO, while both parameters decreased after NIFE, starting from 100 nM 311 
and 300 nM, respectively (Fig. 4c). EHTs paced at 1.5 times baseline frequency and analyzed with 312 
MUSCLEMOTION showed a positive inotropic effect starting from 1 nM ISO and a negative 313 
inotropic effect starting at 30 nM NIFE as previously reported14 (Fig. 4d). 314 
Paced (1 Hz) adult rabbit CMs exhibited no significant increase in relaxation time and contraction 315 
amplitude at any ISO concentration. At concentrations higher than 3 nM, adult CMs exhibited after-316 
contractions and triggered activity during diastole, which hampered their ability to be paced at a fixed 317 
frequency. No significant effects were observed on contraction duration with NIFE, while contraction 318 
amplitude significantly decreased in a dose-dependent manner starting from 100 nM (Fig. 4e). Data 319 
generated by post deflection and sarcomere fractional shortening are available for comparison 320 
purposes in Fig. S6. 321 
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 322 
Analysis of disease phenotypes in vitro 323 
Contractility of hiPSC-CMs carrying mutations associated with Long QT Syndrome Type 1 (LQT1) 324 
and hypertrophic cardiomyopathy (HCM) were characterized in distinct cell configurations: 325 
monolayers plated on MEAs and EHTs, respectively. As demonstrated previously, LQT1 phenotype 326 
was captured as a prolongation of the QT interval of the field potential 16,24 . As expected, contraction 327 
duration measured with MUSCLEMOTION was also prolonged (Fig. 5a,b). EHTs were fabricated 328 
from an isogenic triplet carrying the MYH7R453C mutation in homozygosis and heterozygosis and 329 
showed a gene dosage effect on the contractility recapitulating disease severity.  330 
 331 
 332 
Analysis of disease phenotypes in vivo  333 
To extend analysis to hearts in vivo, we took advantage of the transparency of zebrafish, which allows 334 
recording of contracting cardiac tissue in vivo (Fig. 65a, Movie S109). It was previously shown that 335 
mutations in G protein β subunit 5 (GNB5) are associated with a multisystem syndrome in human, 336 
with severe bradycardia at rest. Zebrafish with loss of function mutations in gnb5a and gnb5b were 337 
generated. Consistent with the syndrome manifestation in patients, zebrafish gnb5a/gnb5b double 338 
mutant embryos showed severe bradycardia in response to parasympathetic activation25. Irregularities 339 
in heart rate were visually evident and were clearly distinguishable from the wild type counterpart 340 
after analysis with MUSCLEMOTION (Fig. 65b). Quantification of the heart rate of these zebrafishes 341 
with MUSCLEMOTION highly correlated (R2 = 0.98) with the results of the published manual 342 
analyses25 (Fig. 65c). There was however, a striking time-saving for operators in carrying out the 343 
analysis using the algorithm (5-10 times faster than manual analysis; 150 recordings were analysed in 344 
5 hours versus 4 days) without compromising accuracy of the outcome. Qualitative analysis of 345 
contraction patterns allowed rapid discrimination between arrhythmic vs non-arrhythmic responses to 346 
carbachol treatment (Fig. 65c). 347 
Finally, we examined human echocardiograms from five healthy and cardiomyopathic individuals 348 
(Fig. 65d, Movie S11). To assess ventricular function, videos were cropped to exclude movement 349 
contributions of the atria and valves. MUSCLEMOTION enabled rapid quantification of temporal 350 
parameters from standard ultrasound echography (Fig. 65e) such as time-to-peak, relaxation time, RR 351 
interval and the contraction duration (Fig. 65f).  352 
 353 
 354 
Discussion 355 
A reliable and easy-to-use method to quantify cardiac muscle contraction would be of significant 356 
benefit to many basic and clinical science laboratories to characterize cardiac disease phenotypes, 357 
understand underlying disease mechanisms and predicting cardiotoxic effects of drugs14,26. 358 
Quantification of frame-to-frame differences in pixel intensity has been used in recent reports with 359 
success10; however, the full spectrum of applications for which these algorithms are relevant, how 360 
their output data correlates with gold standards in each system and software performance, 361 
specifications, license and software availability, have remained unclear.  362 
Here we developed and tested a user-friendly, inexpensive, open source software platform that serves 363 
this purpose in a variety of biological systems of heart tissue. Its integration into current research 364 
practices would benefit data sharing, reproducibility, comparison and translation in many clinically 365 
relevant contexts27. 366 
The linearity and reliability of MUSCLEMOTION were validated using a 3D reconstructed artificial 367 
CM which gave the expected linear correlations between known inputs and the outputs (Fig. 1d-f). 368 
When random repetitive patterns were applied, amplitude outputs differed from inputs, suggesting a 369 
potential limitation to measuring contraction amplitudes in highly repetitive biological samples (such 370 
as when sarcomere patterns are well-organized), while temporal parameters remained valid (Fig. 371 
1d,e,g). However, conditions such as these would be unlikely in standard biological samples, where 372 
camera noise significantly reduces the possibility of saturating pixel movement. We partially 373 
attenuated this problem by applying, on user demand, a 10-sigma Gaussian blur filter which 374 
significantly increased the accuracy of MUSCLEMOTION with highly repetitive structures. Also, to 375 
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increase reliability, we built in additional controls to detect any mismatches and errors. 376 
MUSCLEMOTION can automatically identify and select the reference frame and increase the signal-377 
to-noise-ratio, features which were particularly relevant in reducing user bias and interaction while 378 
improving user experience. MUSCLEMOTION is valid in a wide range of illumination conditions 379 
without changing temporal parameters; however, exposure time was linearly correlated with 380 
contraction amplitude (Fig. S7). Furthermore, a series of situations where no contraction is present 381 
has been used as a negative control (Fig. S8). Batch mode analyses and data storage in custom folders 382 
were also incorporated to support overnight automated analyses. For accurate quantification of 383 
amplitude, time-to-peak and relaxation time, an appropriate sampling rate should be chosen. For 384 
applications similar to those described here, we recommend recording rates higher than 70 frames per 385 
second to sample correctly the fast upstroke of the time-to-peak typical of cardiac tissue. This 386 
recording rate is easily achievable even using smartphone slow motion video options (~120/240 387 
frames per second), obviating the need for dedicated cameras and recording equipment if necessary.  388 
We demonstrated excellent linear correlations between our software tool and multiple other standard 389 
methods independent of substrate, cell configuration and technology platform and showed that 390 
MUSCLEMOTION is able to capture contraction in a wide range of in vivo and in vitro applications 391 
(Fig. 2 and Fig. 3). Specifically, we identified several advantages compared to optical flow algorithms 392 
in terms of speed and the absence of arbitrary binning factors or thresholds which, when modified, 393 
profoundly affect the results. One limitation compared to optical flow or EHT standard algorithm is 394 
that the tool lacks qualitative vector orientation, making it more difficult to assess contraction 395 
direction. Particularly important was the correlation with force data calculated from the displacement 396 
of flexible posts by EHTs. This indicates that when the mechanical properties of substrates are 397 
known28, MUSCLEMOTION allows absolute quantification of contractile force. Technical limitations 398 
of the EHT recording system allowed us to analyze only movies with JPEG compression; this resulted 399 
in loss of pixel information that might have negatively influenced the correlation shown. For better 400 
and more accurate results on contraction quantification, non-lossy/uncompressed video formats 401 
should be used for recordings since individual pixel information is lost upon compression and 402 
therefore not available for analysis by MUSCLEMOTION. 403 
We proposed and validated practical application in pharmacological challenges using multiple 404 
biological preparations recorded in different laboratories; this means that immediate use in multiple 405 
independent high-throughput drug-screening pipelines is possible without further software 406 
development being required, as recently applied for a drug screening protocol on cardiac organoids 407 
from hPSCs17. Intuitively, the possibility of having inter-assay comparisons will also be of particular 408 
relevance where comparisons of contraction data across multiple platforms are required by regulatory 409 
agencies or consortia (e.g. CiPA, CSAHi)5,6,23,29. Moreover, this might offer a quantitative approach to 410 
investigating how genetic or acquired diseases of the heart (e.g. cardiomyopathies7, Long QT 411 
Syndrome30), heart failure resulting from anticancer treatments31,32 or maturation strategies19,33,34 412 
affect cardiac contraction. The possibility of linking in vitro with in vivo assays, with low cost 413 
technologies applicable with existing hardware certainly represents an advantage as demonstrated by 414 
automatic quantification of zebrafish heartbeats and human echocardiograms (Fig. 65). Overall, these 415 
results clearly demonstrated that contraction profiles could be derived and quantified in a wide variety 416 
of commonly used experimental and clinical settings. MUSCLEMOTION might represent a starting 417 
point for a swift screening method to provide clinically relevant insights into regions of limited 418 
contractility in the hearts of patients. We encourage further development of this open source platform 419 
to fit specific needs; future areas of application could include skeletal or smooth muscle in the same 420 
range of formats described here.  421 
MUSCLEMOTION allows the use of a single, transparent method of analysis of cardiac contraction 422 
in many modalities for rapid and reliable identification of disease phenotypes, potential cardiotoxic 423 
effects in drug screening pipelines and translational comparison of contractile behaviour.   424 
 425 
 426 
Limitations 427 
Saturation of pixel movements may affect contraction amplitudes. However, as demonstrated with the 428 
artificial CM, contraction velocity and all temporal parameters remained valid. We also minimized the 429 
 9 
impact of highly repetitive structures on the output of MUSCLEMOTION by applying a Gaussian 430 
filter, which also helped in reducing the impact of transverse movements on contraction profiles. High 431 
frequency contraction might complicate baseline detection, especially if the duration of the contracted 432 
state is similar to that of the relaxed (e.g. approaching sinusoidal). We have implemented a “fast 433 
mode” option that captures reliable baseline values even at high contraction rates. Furthermore, 434 
recordings must be free of moving objects (e.g. debris moved by flow, air bubbles) other than those of 435 
interest. MUSCLEMOTION does not measure absolute values of cell shortening or force of 436 
contraction. However, as demonstrated by correlations with these physical quantities (Fig. 2d,e v) , 437 
specific setups can be calibrated to obtain such readout.  438 
Adult CMs contract dominantly along the longitudinal axis. However, hPSC-CMs highly vary in 439 
shape, often showing concentric contractions, effects of transverse movement are usually intrinsic to 440 
the experimental model and should be considered in the global contraction analysis. Indirect 441 
transverse movements originating from uncontrolled experimental conditions (e.g. sample shift, 442 
floating debris, etc.) should be avoided since it might introduce an overestimation of the 443 
cardiomyocyte contraction. 444 
 445 
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Figures 566 
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Figure 1 569 
Algorithm construction and validation. 570 
a) Principle of pixel intensity difference by subtraction of imgref of imgi and measurement of the non-571 
zero area after image subtraction.  572 
b) Principle of using pixel intensity difference as a measure of displacement and as a measure of 573 
displacement velocity.  574 
c) Schematic overview of MUSCLEMOTION. Green blocks indicate basic steps of the algorithm. 575 
Dark green blocks indicate important user input choices. Plots within light green blocks indicate 576 
results. Optional steps are shown in blue blocks, with graphical representation of the analysed 577 
parameters indicated by red lines. Three result files are generated containing the raw data: 578 
“contraction.txt”, “speed-of-contraction.txt” and “overview-results.txt”. Furthermore, three images 579 
showing relevant traces and a log file are generated and saved (not shown in schematic).  580 
d) Schematic of the contractile pattern of the artificial cell and relative parameters corresponding to 581 
amplitude of contraction (A), time-to-peak (t1) and relaxation time (t2). 582 
e) Correlation between input (x axis) and output (y axis) parameters used to validate 583 
MUSCLEMOTION with two artificial cells. 584 
f-g) Frame representing the two artificial cells built for MUSCLEMOTION validation and their 585 
relative output parameters.  586 
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 587 
 588 
Figure 2 589 
Correlation of results with gold standards.  590 
a) Brightfield image of isolated hPSC-CMs (i), with maximum projection step visually enhanced with 591 
a fire Look Up Table (ii), contraction (iii) and velocity (iv) profiles of each individual beat have been 592 
generated by MUSCLEMOTION and temporally aligned; linear regression analysis between 593 
MUSCLEMOTION results (x-axis) and optical flow results (y-axis) (v). 594 
b) Phase contrast image of hPSC-CM monolayers (i), with maximum projection step visually 595 
enhanced with a fire Look Up Table (ii), contraction (iii) and velocity (iv) profiles of each individual 596 
beat have been generated by MUSCLEMOTION and temporally aligned; linear regression analysis 597 
between MUSCLEMOTION results (x-axis) and those obtained with optical flow results (y-axis) (v). 598 
c) Phase contrast image of cardiac organoids (i), with maximum projection step visually enhanced 599 
with a fire Look Up Table (ii), contraction (iii) and velocity (iv) profiles of each individual beat have 600 
been generated by MUSCLEMOTION and temporally aligned; linear regression analysis between 601 
MUSCLEMOTION results (x-axis) and those obtained with optical flow results (y-axis) (v). 602 
d) Live view of an EHT during contraction analysis. Scale bar = 1 mm. (i), with maximum projection 603 
step visually enhanced with a fire Look Up Table (ii), contraction (iii) and velocity (iv) profiles of 604 
each individual beat have been generated by MUSCLEMOTION and temporally aligned; linear 605 
regression analysis between MUSCLEMOTION results (x-axis) and those obtained with post 606 
deflection (y-axis) (v). 607 
e) Brightfield image of adult rabbit CMs (i), with maximum projection step visually enhanced with a 608 
fire Look Up Table (ii); contraction (iii) and velocity (iv) profiles of each individual beat have been 609 
generated by MUSCLEMOTION and temporally aligned; linear regression analysis between 610 
MUSCLEMOTION results (x-axis) and those obtained from sarcomere fractional shortening 611 
calculation with Fast Fourier Transform (y-axis) (v).  612 
For details on cell sources and cell lines please refer to the Supplementary Table 1.  613 
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 614 
 615 
Figure 3 616 
Application of contraction tool to multiple biological situations. 617 
Representative examples with enhancement of moving pixels (top) and profiles (bottom) of 618 
contraction (a-c, red), velocity (a-c, black) and voltage (a, blue) respectively obtained from high 619 
speed movies of patched hPSC-CMs (a), aligned hPSC-CMs on polyacrylamide gels with fluorescent 620 
beads (b) and hPSC-CMs whose membranes have been labelled with CellMask Deep Red (c). 621 
For details on cell sources and cell lines please refer to the Supplementary Table 1.  622 
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 623 
Figure 4 624 
Pharmacological challenge with positive and negative inotropic compounds. 625 
 18 
a) Average dose-response curves (black traces) and single measurements for several parameters 626 
obtained in isolated, spontaneously beating, aligned hPSC-CMs treated with isoprenaline (left, red) 627 
and nifedipine (right, green).  628 
b) Average dose-response curves (black traces) and single measurements for several parameters 629 
obtained from monolayers of hPSC-CMs treated with isoprenaline (left, red) and nifedipine (right, 630 
green).  631 
c) Average dose-response curves (black traces) and single measurements for several parameters 632 
obtained in cardiac organoids treated with isoprenaline (left, red) and nifedipine (right, green). 633 
d) Average dose-response curves (black traces) and single measurements for several parameters 634 
obtained in EHTs treated with isoprenaline (left, red) and nifedipine (right, green). 635 
e) Average dose-response curves (black traces) and single measurements for several parameters 636 
obtained in adult rabbit CMs treated with isoprenaline (left, red) and verapamil (right, green).  637 
Average data points (black) represent mean ± standard error of mean. For details on cell sources and 638 
cell lines please refer to the Supplementary Table 1.  639 
Data information: P-values DMSO versus dose. Panel a i) 0.3 nM: 0.2897; 1 nM: 3.4·10-6; 3 nM: 640 
3.8·10-8; 10 nM: 7·10-11; 30 nM: 7.3·10-10; 100 nM: 2.4·10-10. Panel a ii) 0.3 nM: 1; 1 nM: 0.0645; 3 641 
nM: 0.0136; 10 nM: 8.2·10-5; 30 nM: 0.0063; 100 nM: 2.4·10-6. (N=14; 14; 14; 14; 14; 14; 14) 642 
Panel a iii) 3 nM: 0.6533; 10 nM: 4·10-5; 30 nM: 2·10-9; 100 nM: 1.5·10-15. Panel a iv) 3 nM: 643 
0.00054; 10 nM: 1.9·10-11; 30 nM: < 2·10-16; 100 nM: < 2·10-16. (N=14; 14; 14; 14; 14) 644 
P-values baseline versus dose. Panel b i) 1 nM: 1; 3 nM: 1; 10 nM: 1; 30 nM: 1; 100 nM: 1; 300 nM: 645 
1. Panel b ii) 1 nM: 1; 3 nM: 1; 10 nM: 1; 30 nM: 1; 100 nM: 1; 300 nM: 1. (N=6; 5; 6; 6; 6; 6; 6) 646 
Panel b iii) 3 nM: 1; 10 nM: 1; 30 nM: 1; 100 nM: 0.00801; 300 nM: 2.7·10-9; 1000 nM: 1.8·10-10. 647 
Panel b iv) 3 nM: 1; 10 nM: 1; 30 nM: 1; 100 nM: 0.00084; 300 nM: 2.9·10-11; 1000 nM: 1.5·10-11. 648 
(N=6; 6; 6; 6; 6; 6; 6) 649 
P-values baseline versus dose. Panel c i) 1 nM: 1; 3 nM: 1; 10 nM: 1; 30 nM: 1; 100 nM: 1; 300 nM: 650 
1. Panel c ii) 1 nM: 1; 3 nM: 1; 10 nM: 1; 30 nM: 1; 100 nM: 1; 300 nM: 1. (N=5; 5; 4; 5; 4; 4; 4) 651 
Panel c iii) 3 nM: 1; 10 nM: 1; 30 nM: 1; 100 nM: 0.00181; 300 nM: 2.9·10-6; 1000 nM: 1.7·10-5. 652 
Panel c iv) 3 nM: 1; 10 nM: 1; 30 nM: 1; 100 nM: 0.54836; 300 nM: 0.01392; 1000 nM: 8.2·10-5. 653 
(N=5; 5; 4; 5; 5; 5; 3) 654 
P-values baseline versus dose. Panel d i) 1 nM: 1; 3 nM: 1; 10 nM: 1; 30 nM: 0.47; 100 nM: 1. Panel 655 
d ii) 1 nM: 0.02318; 3 nM: 0.00170; 10 nM: 0.00028; 30 nM: 0.00044; 100 nM: 0.00113. (N=5; 5; 656 
5; 5; 5; 5). Panel d iii) 3 nM: 1; 10 nM: 1; 30 nM: 1; 100 nM: 3·10-5. Panel d iv) 3 nM: 1; 10 nM: 657 
0.49856; 30 nM: 0.01473; 100 nM: 7·10-6. (N=6; 6; 6; 6; 6) 658 
P-values Krebs versus dose. Panel e i) 1 nM: 1; 3 nM: 1. Panel e ii) 1 nM: 1; 3 nM: 0.54. (N=6; 10; 659 
7)  660 
P-values DMSO versus dose. Panel e iii) 10 nM: 1; 30 nM: 1; 100 nM: 1; 300 nM: 1. Panel e iv) 10 661 
nM: 0.5298; 30 nM: 0.2470; 100 nM: 0.0054; 300 nM: 0.0029. (N=7; 8; 4; 5; 7).  662 
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 663 
 664 
Figure 5 665 
In vitro disease phenotypes. 666 
a) Field potential and contraction profile of wildtype (black) and LQT1 (red) hPSC-CM monolayers 667 
on MEAs. b) Quantitative analysis of the QT interval and the contraction duration. c) Raw (top) and 668 
normalized (bottom) contraction profiles of HCM-EHTs. P-values QT-interval: WT versus LQT1: 669 
0.012. P-values contraction duration: WT versus LQT1: 0.012. d) Quantitative analysis of 670 
contraction amplitude and contraction duration. P-values contraction amplitude: MYH7wt/wt versus 671 
MYH7wt/mut: 0.026; MYH7wt/wt versus MYH7mut/mut: 6·10-6; MYH7wt/mut versus MYH7mut/mut: 672 
0.00065. P-values contraction duration: MYH7wt/wt versus MYH7wt/mut: 0.062; MYH7wt/wt versus 673 
MYH7mut/mut: 0.00085; MYH7wt/mut versus MYH7mut/mut: 0.0046. 674 
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 678 
Figure 65 679 
In vivo disease phenotypes. 680 
a) Representative examples of wild type (top) and gnb5a/gnb5b mutant (bottom) zebrafishes and 681 
relative enhancement of moving pixels.   682 
b) Representative qualitative analyses of normal (top) and arrhythmic (bottom) contraction profiles 683 
from wild type and gnb5a/gnb5b mutant zebrafishes treated with carbachol. 684 
c) Correlation of results obtained from manual (x-axis) vs automatic (y-axis) detection of beating 685 
frequency (top); distribution of normal (green) and arrhythmic (red) contraction patterns in baseline 686 
condition (B) and after treatment with carbachol (C) in wild type and gnb5a/gnb5b mutant zebrafishes 687 
(bottom). 688 
d) Representative echocardiograms of healthy (top) and cardiomyopathic (bottom) human 689 
individuals. Ventricles have been manually cropped and the enhancement of moving pixels is 690 
overlaid. 691 
e) Representative qualitative analyses of normal (top) and poor (bottom) ventricular functions.  692 
f) Quantitative data collected from echocardiogram in 5 individuals. Each colour represents one 693 
individual. 694 
